Key result
Sabin-strain IPV shows comparable immunogenicity to conventional Salk-strain IPV in healthy infants.
Why the study?
Poliomyelitis remains a threat to young children, and sIPV has emerged as a safer alternative to conventional Salk-strain IPV due to lower biosafety requirements.
Does Sabin-strain inactivated poliovirus vaccine (sIPV) provide comparable immunogenicity and safety to conventional Salk-strain IPV (cIPV) in healthy infants?
Meta-Analysis (n=4,646)
Does Sabin-strain inactivated poliovirus vaccine (sIPV) provide comparable immunogenicity and safety to conventional Salk-strain IPV (cIPV) in healthy infants?
Effect estimate: RR 1.00 (95% CI 1.00-1.01)
Sabin-strain IPV provides comparable immunogenicity to conventional Salk-strain IPV with an acceptable safety profile, supporting its use as a safer-to-manufacture alternative in global polio eradication programs.
Supports interchangeable inactivated vaccine use in immunization; confirms equivalent immunogenicity across serotypes in Level 1 meta-analysis.
BACKGROUND: Poliomyelitis remains a threat to children under five despite global vaccination efforts. The Sabin-strain inactivated poliovirus vaccine (sIPV) has emerged as a safer alternative to conventional Salk-strain IPV (cIPV) due to lower biosafety requirements. This systematic review and meta-analysis evaluated the immunogenicity and safety of sIPV compared with cIPV in healthy infants completing the primary IPV series. METHODS: PubMed, Embase, Scopus, and Cochrane Library were searched for RCTs. Outcomes included seroconversion rates, seroprotection rates, geometric mean titers (GMTs), and adverse events. Data were pooled using random-effects models, and evidence certainty was assessed using RoB 2.0 and GRADE. RESULTS: Seven RCTs with 4646 infants were included. Seroconversion rates were comparable: PV1 100% (RR 1.00, 95% CI 1.00-1.01), PV2 102% (RR 1.02, 95% CI 0.98-1.07), PV3 100% (RR 1.00, 95% CI 0.99-1.01). GMTs were higher for sIPV after PV1 (MD 1.50, 95% CI 0.98-2.02) and PV2 (MD 0.52, 95% CI 0.06-0.98). Local adverse events were similar (OR 1.27, 95% CI 0.95-1.71), while systemic adverse events were higher with cIPV (OR 1.36, 95% CI 1.15-1.60). Fever (OR 1.50, 95% CI 1.20-1.87) and allergic reactions (OR 2.19, 95% CI 1.02-4.69) were slightly more frequent with sIPV. CONCLUSIONS: sIPV provides immunogenicity comparable to cIPV with an acceptable safety profile in infants. Its lower biosafety requirements support its use in global polio eradication programs.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2026) conducted a meta-analysis in Poliomyelitis (n=4,646). Sabin-strain inactivated poliovirus vaccine (sIPV) vs. conventional Salk-strain IPV (cIPV) was evaluated on Seroconversion rate for PV1 (RR 1.00, 95% CI 1.00-1.01). Sabin-strain inactivated poliovirus vaccine (sIPV) demonstrated comparable immunogenicity to conventional Salk-strain IPV, with a PV1 seroconversion RR of 1.00 (95% CI 1.00-1.01) in healthy infants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: